Intensity Therapeutics INTS
NASDAQ INTS
$3.42 -0.23 (-6.28%)
As of: Sep 29, 2026 · 3:55 PM EDT

Intensity Therapeutics (INTS) Interest Expenses (2022 - 2023)

Updated

Intensity Therapeutics (INTS) recorded Interest Expenses of $305,000 in FY2023, up 272.0% from $82,000 in FY2022.

Analysis

Intensity Therapeutics (INTS) Interest Expenses (2022 - 2023) Analysis & Trends

  • Per Business Quant data, INTS's Interest Expenses was $82,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 281.00 Mn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -435.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 247.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Intensity Therapeutics 10.75 Mn 10.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 222,000.00
Mar 31, 2023 83,000.00
Dec 31, 2022 37,123.00
Sep 30, 2022 15,123.00
Jun 30, 2022 14,959.00
API Access

Intensity Therapeutics Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-expenses&ticker=INTS&period=max&api_key=YOUR_API_KEY